DALLAS, January 15, 2015 /PRNewswire/ --
LifeScienceIndustryResearch.com adds Therapeutic Class Overview: Moderate to Severe Pain: Novel Abuse Deterrent Formulation Technologies and Emergence of Novel Mechanisms in the Management of Pain, a 2015 market research report of 64 pages to its intelligence library.
This pain management therapy market report discusses a number of novel delivery technologies employed in the formulation of abuse deterrent product, technologies employed in enhancing patient compliances and emerging novel mechanisms in the management of pain. Renewed interest on pain therapy is vision as recently Biogen Idec acquired Convergence's CNV1014802 (Nav 1.7 sodium channel blocker) to expand its neuropathic pain portfolio and we believe several such acquisitions will happen in the near term. Complete research is available at http://www.lifescienceindustryresearch.com/therapeutic-class-overview-moderate-to-severe-pain-novel-abuse-deterrent-formulation-technologies-and-emergence-of-novel-mechanisms-in-the-management-of-pain.html .
Pain is the leading cause of disability in the US, affecting more than cancer, diabetes and heart disease combined. Current analgesics for persistent pain are relatively ineffective, are associated with significant adverse effects or abuse liability, and do not reduce pain in all treated individuals. Opioids (e.g., morphine, codeine, oxycodone) are currently one of the most potent groups of analgesics used clinically, with prescriptions increasing by 50% over the past 10 years for chronic, non-cancer pain. However, there is clear evidence that as opioid prescription rate rise, there is a corresponding increase in opioid overdose deaths, misuse and addiction. These adverse effects are attributed to the opioid agonist effects on central opioid receptors-causing dependence, tolerance, sedation, and respiratory depression.
Non-steroidal and steroidal anti-inflammatory drugs have serious side effects such as gastric erosions, ulcer formation, bleeding, hypersensitivity reactions, cardiovascular toxicity, renal toxicity, and hepatotoxicity. In addition, they are also not peripherally selective thereby causing a range of central adverse effects. Over the past 20 years, most analgesic development activities have been limited to the reformulation of opioids, production of new cyclooxygenase (COX) inhibitors, amine reuptake inhibitors and anticonvulsants, and introduction of topical local anesthetics-all of these act on well-established targets. A significant unmet need exists in the emergence of novel mechanism which will avoid the current NSAIDS side effects with improved efficacy. Several newer mechanisms currently being explored will have the ability to replace opioids in the treatment of acute and chronic moderate to severe pain.
Globally, pain is one of the important therapy areas with a market size of over $50b in 2013, and is expected to grow at 10%. The recent patent expiry of Cymbalta and Lyrica (2018) will have significant impact on the overall pain market size in the near future. However, several pipeline molecules are emerging to fill this gap. The importance of abuse deterrent labeling in the formulations can be better understood from FDA's non-approval of oxycontin generics in 2013. The revised labeling with abuse deterrence has protected Purdue's oxycontin revenue slide from its generization.
In the wake of abusive potential of opioids drugs reported all across the US, FDA recently drafted guidance for evaluation and labeling of opioids formulations based on their ability to reduce its abusive potential (tier 1 to 4). Despite the process being in nascent stage, several specialty companies have already ventured into the development of abuse deterrent formulations to reap benefits in the near future.
FDA Perspective on Abuse deterrent formulations (Opioids) Companies mentioned in this research include: AbbVie, AcelRx, Acorda Therapeutics, Actavis, Acura Pharma, Altus formulations, Amorsa Therapeutics, AstraZeneca, BioDelivery Sciences International Inc, Cara Therapeutics, Catalent, Charleston, Collegium Pharma, Convergence, Daiichi, Daewoong, Pain Management, Depomed, Durect, Egalet, Eli Lilly, Elite Pharma, Endo, Flamel Technologies, Flexion Therapeutics, Glenmark, Grunenthal, Immune Pharmaceuticals, Impax Pharmaceuticals, Inspirion Delivery technologies, Intelli Pharmaceutics, Johnson and Johnson, KemPharm, Kineta, Kunwha Pharmaceutical, Medallion Therapeutics, Nektar, Orbis Biosciences, Orexo, Pain Therapeutics, Pfizer, Purdue, Recro, Relmada Therapeutics, Signature Therapeutics, Spinifex pharma, SPR Therapeutics, Teikoku, Teva, Trevena Inc, Tris Pharma, Valeant, Xenon Pharma and XenoPort. Order a copy of this report at http://www.lifescienceindustryresearch.com/purchase?rname=30610 .
More reports on pain and related sectors of pharmaceuticals industry research are available with LifeScienceIndustryResearch.com:
Moderate Pain-Pipeline Review, H2 2014: A 87 pages market research report, this study provides comprehensive information on the therapeutic development for Moderate Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Moderate Pain and special features on late-stage and discontinued projects
The Peripheral Neuropathic Pain-Pipeline Review, H2 2014 market research report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities. The report reviews key players involved in the therapeutics development for Peripheral Neuropathic Pain and enlists all their major and minor projects while summarizing all the dormant and discontinued pipeline projects. A review of the Peripheral Neuropathic Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources is provided along with pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages. A detailed assessment of monotherapy and combination therapy pipeline projects, Coverage of the Peripheral Neuropathic Pain pipeline on the basis of target, MoA, route of administration and molecule type as well as latest news and deals relating related to pipeline products are covered in this research available at http://www.lifescienceindustryresearch.com/peripheral-neuropathic-pain-pipeline-review-h2-2014.html .
About Us:
Life Science Industry Researchbrings to you to the latest reports in market research on Biotechnology, Diagnostics, Healthcare, Medical Devices and Pharmaceuticals segments from leading research publishers across the globe. These reports also cover data and information on sub-segments and sectors under these life sciences categories.
Contact:
Priyank Tiwari / Ritesh Tiwari
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Tel: +1-888-391-5441
sales@lifescienceindustryresearch.com
Connect with Us:
G+ / Google Plus:https://plus.google.com/112612135957880308475/about
Twitter:https://twitter.com/LifeSciReports
RSS / Feeds:http://www.lifescienceindustryresearch.com/feed
